Management of HIV/AIDS

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

Monday, May 18, 2020 - 11:00am

Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.

Key Points: 
  • Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

Wednesday, May 13, 2020 - 1:00pm

Two presentations provide the first description of a novel approach to potentially cure HIV.

Key Points: 
  • Two presentations provide the first description of a novel approach to potentially cure HIV.
  • Two people the London Patient and the Berlin Patient have been cured of HIV following transplantation of cells with genetic mutations that prevent HIV infection.
  • Currently, we have good oral, safe and effective therapies that patients with HIV or chronic HBV must take daily, for life.
  • Non-compliance can lead to HIV and HBV viral resistance or to acute liver flares in patients with chronic liver disease.

CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020

Wednesday, May 13, 2020 - 11:00am

After the BLA submission is deemed completed, the FDA assigns a Prescription Drug User Fee Act (PDUFA) goal date.

Key Points: 
  • After the BLA submission is deemed completed, the FDA assigns a Prescription Drug User Fee Act (PDUFA) goal date.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • After the BLA submission is considered completed, the FDA will make a filing decision and set a PDUFA goal date.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

CytoDyn Clarifies Status of Biologics License Application

Saturday, May 9, 2020 - 12:59am

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.

Key Points: 
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.

Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients

Thursday, May 7, 2020 - 11:19pm

Leronlimab has been administered to 54 severely and critically ill COVID-19 patients thus far under Emergency Investigational New Drug (EINDs) authorizations granted by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Leronlimab has been administered to 54 severely and critically ill COVID-19 patients thus far under Emergency Investigational New Drug (EINDs) authorizations granted by the U.S. Food and Drug Administration (FDA).
  • Since initiating the leronlimab mild/moderate last month, Novant Health has screened nearly 400 patients for eligibility.
  • Expanding treatment options for our more critically ill patients is a vital step in our fight against COVID-19.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

Monday, April 27, 2020 - 2:20pm

Food and Drug Administration(FDA) of the proprietary name Vyrologix (pronounced - vie-ro-loj-iks) for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States.

Key Points: 
  • Food and Drug Administration(FDA) of the proprietary name Vyrologix (pronounced - vie-ro-loj-iks) for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States.
  • We are pleased to receive the FDAs conditional acceptance of Vyrologix as the proprietary name for leronlimabs combination therapy treatment of HIV, said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients.

CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

Monday, April 27, 2020 - 2:12pm

The FDA previously granted both Fast Track designation for leronlimab and rolling review for the Companys BLA in HIV indication.

Key Points: 
  • The FDA previously granted both Fast Track designation for leronlimab and rolling review for the Companys BLA in HIV indication.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients.

US HIV Market and Competitive Landscape (2019 to 2025) - Track Competitive Developments - ResearchAndMarkets.com

Friday, April 17, 2020 - 7:06pm

The "US HIV Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US HIV Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US HIV Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into HIV pipeline products, HIV epidemiology, HIV market valuations and forecast, HIV drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - HIV treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for HIV products

CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK” Livestream Event on April 17, 2020 at 12:30 pm ET / 9:30 am PT

Thursday, April 16, 2020 - 11:00am

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

Key Points: 
  • CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.